Tranzyme Inc (NASDAQ:TZYM): Following its meeting with the company’s management, Stifel Nicolaus predicts that the data regarding its TZP-102 drug, which should be out by 2012’s end, will significantly raise interest from possible collaborators/acquirers. The firm believes that the drug, a treatment for diabetic gastroparesis, will succeed. The firm keeps its Buy rating on the stock.
PPG Industries Inc. (NYSE:PPG): According to Baird, the divesture of the company’s commodity chemicals business is positive for its shares, and the firm predicts a favorable market reaction. The firm noted its Coatings niche focus providing stable growth, strong pricing power, and substantial free cash flow. Shares have an Outperform rating and a $120 price target.
Mellanox Technologies, Ltd. (NASDAQ:MLNX) target was increased by ThinkEquity after the company’s report of a Q2 EPS which exceeded expectations as well as providing Q3 revenue guidance which surpassed expectations. The firm believes that company will see a boost due to the anticipated launch of Microsoft’s (NASDAQ:MSFT) next-generation Windows Server offering. The firm keep a Buy rating on the stock.
NuVasive, Inc. (NASDAQ:NUVA): Following checks, ThinkEquity reports that the spine market is still challenged but stable. The firm predicts that NuVasive is ready to report Q2 results which are stronger than expected. The firm keeps a Buy rating on the stock.
Skyworks Solutions Inc. (NASDAQ:SWKS) has reported a Q3 revenue surpassing expectations causing ThinkEquity to increase the stocks price target from $31 to $36. The firm keeps a Buy rating on the stock.
Don’t Miss: Apple Has MAJOR UPSET in Samsung Battle.
Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.